Related Experiment Video
Updated: Sep 21, 2026
Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
Published on: March 5, 2012
In silico approach to probe the binding affinity between OMVs harboring the ZEGFR affibody and the EGF receptor
Zahra Sepahdar1, Reza Saghiri2, Mehran Miroliaei3
1Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.
Abstract:
There is a growing interest in designing a nanocarrier containing an EGFR targeting affibody to direct toward cancer cells. Here, cytolysin A was cloned at the N-terminus of ZEGFR:1907 affibody to guarantee its surface presentation on the OMVs while targeting the epidermal growth factor receptors (EGFRs). A separate construct including a fusogenic peptide (GALA) was also designed for the endosomal escape of the nanocarrier. Binding of the two constructs ClyA-affiEGFR and ClyA-affiEGFR-GALA to domain III of EGFR was investigated using molecular docking and molecular dynamic simulations. The higher stability of the ClyA-affiEGFR-GALA/EGFR as compared to the ClyA-affiEGFR/EGFR complex was evident. The ClyA-affiEGFR-GALA structure showed a higher RMSD during the first half of the simulation time implying a much less stable behavior. Plateau state of the radius of gyration plot of ClyA-affiEGFR-GALA confirmed a well-folded structure in the presence of the GALA sequence. Solvent accessible surface area for both proteins was in the same range. The data obtained from hydrogen bond analysis revealed a more equilibrated and stable form of the ClyA-affiEGFR-GALA structure upon interaction with EGFR. The data provided here was a requisite for our biological evaluation of the synthesized constructs as a component of a novel drug delivery system.
Insights
Researchers engineered a novel nanocarrier using cytolysin A and an EGFR-targeting affibody for cancer therapy. The addition of a GALA peptide enhanced nanocarrier stability and EGFR binding, paving the way for advanced drug delivery systems.
Area of Science:
- Biotechnology and Nanomedicine
- Molecular Biology
- Computational Chemistry
Background:
- Developing targeted nanocarriers for cancer therapy is crucial.
- Epidermal Growth Factor Receptors (EGFRs) are key targets in many cancers.
- Affibodies offer specific targeting capabilities for therapeutic agents.
Purpose of the Study:
- To design and computationally evaluate a novel nanocarrier for EGFR-targeted cancer therapy.
- To investigate the surface presentation and stability of engineered nanocarriers.
- To assess the role of a fusogenic peptide in nanocarrier function.
Main Methods:
- Molecular docking and molecular dynamic simulations were employed.
- Engineered constructs included Cytolysin A (ClyA) fused with an EGFR-targeting affibody (ZEGFR:1907).
- A fusogenic peptide (GALA) was incorporated into one construct for enhanced endosomal escape.
Main Results:
- The ClyA-affiEGFR-GALA construct demonstrated higher stability and a more equilibrated interaction with EGFR compared to ClyA-affiEGFR.
- Molecular dynamics simulations indicated a well-folded structure for ClyA-affiEGFR-GALA.
- Hydrogen bond analysis confirmed the enhanced stability of the ClyA-affiEGFR-GALA/EGFR complex.
Conclusions:
- The engineered ClyA-affiEGFR-GALA construct shows promise as a stable nanocarrier for EGFR-targeted drug delivery.
- Computational data supports the potential of this nanocarrier for biological evaluation.
- This study provides a foundation for developing novel cancer nanotherapeutics.
